Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities

VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0) “HYTN” or “The Company”, a leader in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce, further to its news release dated June 13, 2024, the completion of its…

Silo Pharma Press

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of…

Clearmind Press

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced a strategic engagement with JS First Sdn. Bhd (“JS First”). This partnership aims to source global manufacturers and distributors for…

Silo Pharma Press

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical…

MindMed Press

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety…

Psyched Wellness Press

Psyched Wellness Adds Harmons to List of Retail Partners, Engages UNFI For Distribution, and Announces Appointment of Kyle Nazareth as Chief Financial Officer

Toronto, Ontario–(Newsfile Corp. – July 17, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to update the markets with the latest list of specialty retailers…

Health & Science

Psilocybin Offers Promising Relief for Cluster Headaches

Cluster headaches are a debilitating type of headache characterized by excruciating pain, often localized to one side of the head or behind one eye. These headaches can last from 15 minutes to three hours, striking suddenly and frequently recurring multiple times a day. The intensity of the pain experienced during cluster headaches is often severe…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.